130 related articles for article (PubMed ID: 14642736)
21. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives.
Gamboa da Costa G; McDaniel-Hamilton LP; Heflich RH; Marques MM; Beland FA
Carcinogenesis; 2001 Aug; 22(8):1307-15. PubMed ID: 11470763
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the major DNA adduct formed by alpha-hydroxy-N-desmethyltamoxifen in vitro and in vivo.
Gamboa da Costa G; Hamilton LP; Beland FA; Marques MM
Chem Res Toxicol; 2000 Mar; 13(3):200-7. PubMed ID: 10725117
[TBL] [Abstract][Full Text] [Related]
23. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Dehal SS; Kupfer D
Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
[TBL] [Abstract][Full Text] [Related]
24. 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.
Arlt VM; Hewer A; Sorg BL; Schmeiser HH; Phillips DH; Stiborova M
Chem Res Toxicol; 2004 Aug; 17(8):1092-101. PubMed ID: 15310241
[TBL] [Abstract][Full Text] [Related]
25. Lack of genotoxicity of tamoxifen in human endometrium.
Carmichael PL; Ugwumadu AH; Neven P; Hewer AJ; Poon GK; Phillips DH
Cancer Res; 1996 Apr; 56(7):1475-9. PubMed ID: 8603387
[TBL] [Abstract][Full Text] [Related]
26. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture.
Glatt H; Davis W; Meinl W; Hermersdörfer H; Venitt S; Phillips DH
Carcinogenesis; 1998 Oct; 19(10):1709-13. PubMed ID: 9806149
[TBL] [Abstract][Full Text] [Related]
27. The K-region trans-8,9-diol does not significantly contribute as an intermediate in the metabolic activation of dibenzo[a,l]pyrene to DNA-binding metabolites by human cytochrome P450 1A1 or 1B1.
Luch A; Kishiyama S; Seidel A; Doehmer J; Greim H; Baird WM
Cancer Res; 1999 Sep; 59(18):4603-9. PubMed ID: 10493514
[TBL] [Abstract][Full Text] [Related]
28. Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.
Bekaii-Saab TS; Perloff MD; Weemhoff JL; Greenblatt DJ; von Moltke LL
Biopharm Drug Dispos; 2004 Oct; 25(7):283-9. PubMed ID: 15386482
[TBL] [Abstract][Full Text] [Related]
29. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.
Parte P; Kupfer D
Drug Metab Dispos; 2005 Oct; 33(10):1446-52. PubMed ID: 15987777
[TBL] [Abstract][Full Text] [Related]
30. Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling.
Beland FA; Churchwell MI; Hewer A; Phillips DH; Gamboa da Costa G; Marques MM
Biochem Biophys Res Commun; 2004 Jul; 320(2):297-302. PubMed ID: 15219826
[TBL] [Abstract][Full Text] [Related]
31. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
32. A quantitative comparison of dibenzo[a,l]pyrene-DNA adduct formation by recombinant human cytochrome P450 microsomes.
King LC; Adams L; Allison J; Kohan MJ; Nelson G; Desai D; Amin S; Ross JA
Mol Carcinog; 1999 Oct; 26(2):74-82. PubMed ID: 10506751
[TBL] [Abstract][Full Text] [Related]
33. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450.
Williams ML; Lennard MS; Martin IJ; Tucker GT
Carcinogenesis; 1994 Dec; 15(12):2733-8. PubMed ID: 8001229
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans.
White IN
Curr Drug Metab; 2003 Jun; 4(3):223-39. PubMed ID: 12769667
[TBL] [Abstract][Full Text] [Related]
35. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.
Singh MN; Stringfellow HF; Walsh MJ; Ashton KM; Paraskevaidis E; Abdo KR; Martin-Hirsch PL; Phillips DH; Martin FL
Toxicology; 2008 Jul; 249(1):85-90. PubMed ID: 18502016
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
37. N-demethylation accompanies alpha-hydroxylation in the metabolic activation of tamoxifen in rat liver cells.
Phillips DH; Hewer A; Horton MN; Cole KJ; Carmichael PL; Davis W; Osborne MR
Carcinogenesis; 1999 Oct; 20(10):2003-9. PubMed ID: 10506117
[TBL] [Abstract][Full Text] [Related]
38. Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Marques MM; Fu X; Churchwell MI; Wang YP; Doerge DR; Beland FA
Cancer Lett; 2007 Nov; 257(2):191-8. PubMed ID: 17765393
[TBL] [Abstract][Full Text] [Related]
39. Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes.
Cotreau-Bibbo MM; von Moltke LL; Greenblatt DJ
J Pharm Sci; 1996 Nov; 85(11):1180-5. PubMed ID: 8923322
[TBL] [Abstract][Full Text] [Related]
40. Stereoselective metabolic activation of alpha-hydroxy-N-desmethyltamoxifen: the R-isomer forms more DNA adducts in rat liver cells.
Osborne MR; Hewer A; Phillips DH
Chem Res Toxicol; 2004 May; 17(5):697-701. PubMed ID: 15144227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
